WT1 W10

Drug Profile

WT1 W10

Alternative Names: WT1 W10

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NEC Corporation
  • Developer Kochi University; NEC Corporation
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Phase I Glioblastoma
  • Clinical Phase Unknown Pancreatic cancer

Most Recent Events

  • 19 Feb 2018 NEC Corporation completes a clinical trial for Pancreatic cancer (Adjunctive treatment) in Japan (UMIN000026187)
  • 09 Feb 2018 NEC corporation completes a clinical trial in Pancreatic cancer (Second-line therapy or greater, Adjunctive treatment, In adults, In the elderly) in Japan (Intradermal) (UMIN000026049)
  • 31 May 2017 NEC Corporation and Kochi University completes a clinical trial in Pancreatic cancer (Second-line therapy or greater, Adjunctive therapy) in Japan before May 2017 (UMIN000027565)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top